Vietnam Receives 2,873,520 Additional Pfizer Vaccine Doses from COVAX Made Available by the United States

HANOI, November 8, 2021 - The U.S. Mission to Vietnam is proud to partner with Vietnam to combat the COVID-19 pandemic.  The United States, in partnership with COVAX, is providing 2,873,520 additional life-saving doses of the Pfizer-BioNTech vaccine to Vietnam.  1,316,250 doses arrived on November 6 in Hanoi, and 1,557,270 doses arrived in two shipments on November 7 and 8 in Ho Chi Minh City.  This is the seventh delivery to Vietnam, totaling more than 15 million COVID-19 vaccine doses made available by the United States.

The United States has committed more than $30.2 million in COVID-19 related assistance for Vietnam since the beginning of the pandemic.  Building on our longstanding cooperation and investment in Vietnam’s health infrastructure, we have provided support to essentially every pillar of the country’s pandemic response.  From virtual trainings that have reached thousands of hospital workers, to genetic sequencing technology that allows Vietnam to track variants of the virus, to equipment for testing and for vaccine storage, to life-saving equipment, such as ventilators, oxygen concentrators, and liquid-oxygen tanks for patients in need.  We stand shoulder-to-shoulder with Vietnam in the fight against COVID-19. 

At the Global COVID-⁠19 Summit on September 22, the President announced a commitment to provide an additional 500 million Pfizer doses to 92 low- and middle-income countries and economies around the world, and the African Union, bringing the U.S. total global commitment to more than 1.1 billion doses.  Vietnam has been a leading recipient of these doses.  

Worldwide, the United States has provided more than 220 million doses of COVID-19 vaccines to more than 100 countries and economies.  We will continue to provide additional vaccine doses globally as supply becomes available.  We are also working with U.S. vaccine manufacturers to increase vaccine supply for the rest of the world and with partners to expand global vaccine production and manufacturing capacity to beat this pandemic.